Association Between Some Polymorphisms in Apelin/ Apelin Receptor Genes and Coronary Artery Disease in Syrian Patients

NCT05562687 | Completed

• 1 other identifier: UDFP-Chemical-02-2022
• Study Type: observational
• Target: 223
• Locations: 1 country
• Sites: 1

Brief Summary

The apelin-APJ signaling pathway has emerged as an important novel mediator of cardiovascular control and blood pressure homeostasis. Genetic variation in apelin and its receptors likely contributes to essential hypertension, in addition to a range of traditional risk factors. Thus, a study will be conducted on Syrian patients with hypertension and coronary artery disease to investigate some of the single polymorphisms in the apelin gene and its receptor that may be responsible for the development of these diseases, and to link the levels of this peptide and its receptor in the blood with these polymorphisms and the percentage of these diseases (as shown by many Modern Global Reference Studies).

Conditions

Hypertension; Coronary Artery Disease

Keywords

Apelin; Apelin receptor (APJ); Coronary Artery Disease (CAD); Hypertension; apelin -1860T>C polymorphism; APJ G212A polymorphism

Outcome Measures

Primary Outcomes (4)

• Blood apelin concentrations

  Blood samples will be obtained after a 10-h overnight fast before angiography and centrifuged at 1000 g for 10 min, then plasma specimens were stored at -80°C until analysis.

  Collecting blood samples before angiography

• Blood apelin receptor (APJ) concentrations

  Blood samples will be obtained after a 10-h overnight fast before angiography and centrifuged at 1000 g for 10 min, then plasma specimens were stored at -80°C until analysis

  Collecting blood samples before angiography

• The allelic and genotypic frequencies of the -1860T>C single polymorphism nucleotides of the apelin genes

  Genomic DNA will be extracted from peripheral blood sample, after that DNA will be stored in a deep freezer (-80°C) until the genetic analysis

  Collecting blood samples before angiography

• The allelic and genotypic frequencies of the G212A single polymorphism nucleotides of the apelin receptor genes

  Genomic DNA will be extracted from peripheral blood sample, after that DNA will be stored in a deep freezer (-80°C) until the genetic analysis.

  Collecting blood samples before angiography

Secondary Outcomes (6)

• BMI

  before angiography

• Measurement of blood pressure

  before angiography

• Plasma levels of triglycerides (TG)

  Collecting blood samples before angiography

• total cholesterol (TC) levels in plasma

  Collecting blood samples before angiography

• high-density lipoprotein cholesterol (HDL-C) levels in plasma

  Collecting blood samples before angiography

Study Arms (4)

Control group

subjects who do not have any heart disease, hypertension, or other chronic \&inflammatory diseases, and their coronary arteries are normal

CAD group with essential hypertension

subjects who have stenosis (at least 70%) of one of the main coronary arteries or its branches and have high blood pressure

CAD group without essential hypertension

subjects who have stenosis (at least 70%) of one of the main coronary arteries or its branches and have normal blood pressure

Hypertension group without CAD

the subjects were characterized by the normal coronary artery and high blood pressure

Eligibility Criteria

• Age: 30 Years - 78 Years
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

* Control group: subjects who do not have any heart disease, hypertension, or other chronic \&inflammatory diseases, and their coronary arteries are normal. * CAD group with essential hypertension: subjects who have stenosis (at least 70%) of one of the main coronary arteries or its branches and have high blood pressure * CAD group without essential hypertension: subjects who have stenosis (at least 70%) of one of the main coronary arteries or its branches and have normal blood pressure * Hypertension group without CAD: the subjects were characterized by the normal coronary artery and high blood pressure.

You may qualify if:

• Control group: the subjects were characterized by no history of angina and other heart disease or hypertension, and do not have other chronic or inflammatory diseases.
• They represent a normal resting ECG and normal exercise ECG stress testing. And the angiography showed the absence of any stenosis of the coronary arteries.
• They were matched with CAD patients according to age, gender and ethnicity.
• CAD group with essential hypertension: the subjects were characterized by at least 70% stenosis in any coronary artery and high blood pressure (the average of three blood pressure readings was at least 140 mmHg systolic or 90 mmHg diastolic).
• CAD group without essential hypertension: the subjects were characterized by at least 70% stenosis in any coronary artery and normal blood pressure.
• Hypertension group without CAD: the subjects were characterized by the normal coronary artery and high blood pressure. And they were characterized by no history of angina and other heart disease or hypertension, and do not have other chronic or inflammatory diseases.

You may not qualify if:

• Individuals with valvular heart disease, cardiomyopathy, chronic kidney disease, diabetes, and inflammatory disease were excluded

Sponsors & Collaborators

• Damascus University: lead

Study Sites (1)

Damascus University- Faculty of Pharmacy- Research and Graduate Studies Laboratory

Damascus, 011, Syria

Location

Related Publications (8)

• Wang T, Liu C, Jia L, Ding J. The association between apelin polymorphisms and hypertension in China: A meta-analysis. J Renin Angiotensin Aldosterone Syst. 2019 Jan-Mar;20(1):1470320319827204. doi: 10.1177/1470320319827204.

  PMID: 30755060 BACKGROUND

• Zhong JC, Zhang ZZ, Wang W, McKinnie SMK, Vederas JC, Oudit GY. Targeting the apelin pathway as a novel therapeutic approach for cardiovascular diseases. Biochim Biophys Acta Mol Basis Dis. 2017 Aug;1863(8):1942-1950. doi: 10.1016/j.bbadis.2016.11.007. Epub 2016 Nov 4.

  PMID: 27825851 BACKGROUND

• Jin W, Su X, Xu M, Liu Y, Shi J, Lu L, Niu W. Interactive association of five candidate polymorphisms in Apelin/APJ pathway with coronary artery disease among Chinese hypertensive patients. PLoS One. 2012;7(12):e51123. doi: 10.1371/journal.pone.0051123. Epub 2012 Dec 3.

  PMID: 23226564 BACKGROUND

• Falcone C, Bozzini S, Schirinzi S, Buzzi MP, Boiocchi C, Totaro R, Bondesan M, Pelissero G. APJ polymorphisms in coronary artery disease patients with and without hypertension. Mol Med Rep. 2012 Feb;5(2):321-5. doi: 10.3892/mmr.2011.685. Epub 2011 Nov 21.

  PMID: 22109355 BACKGROUND

• Akcilar R, Yumun G, Bayat Z, Donbaloglu O, Erselcan K, Ece E, Kokdasgil H, Genc O. Characterization of the apelin -1860T>C polymorphism in Turkish coronary artery disease patients and healthy individuals. Int J Physiol Pathophysiol Pharmacol. 2015 Dec 25;7(4):165-71. eCollection 2015.

  PMID: 27073592 BACKGROUND

• Huang F, Zhu P, Huang Q, Yuan Y, Lin F, Li Q. Associations between gene polymorphisms of the apelin-APJ system and the risk of hypertension. Blood Press. 2016 Aug;25(4):257-62. doi: 10.3109/08037051.2016.1156905. Epub 2016 Jun 24.

  PMID: 27338090 BACKGROUND

• Nowzari Z, Masoumi M, Nazari-Robati M, Akbari H, Shahrokhi N, Asadikaram G. Association of polymorphisms of leptin, leptin receptor and apelin receptor genes with susceptibility to coronary artery disease and hypertension. Life Sci. 2018 Aug 15;207:166-171. doi: 10.1016/j.lfs.2018.06.007. Epub 2018 Jun 6.

  PMID: 29883719 BACKGROUND

• Castan-Laurell I, Dray C, Valet P. The therapeutic potentials of apelin in obesity-associated diseases. Mol Cell Endocrinol. 2021 Jun 1;529:111278. doi: 10.1016/j.mce.2021.111278. Epub 2021 Apr 7.

  PMID: 33838166 BACKGROUND

MeSH Terms

Conditions

Coronary Artery Disease; Hypertension

Condition Hierarchy (Ancestors)

Coronary Disease; Myocardial Ischemia; Heart Diseases; Cardiovascular Diseases; Arteriosclerosis; Arterial Occlusive Diseases; Vascular Diseases

Study Officials

• Hussam Eddin Mohammed Shibli, PhD

  Damascus university, ASPU Al-Sham Private University

  STUDY DIRECTOR

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 28, 2022
• First Posted: October 3, 2022
• Study Start: December 15, 2019
• Primary Completion: January 5, 2022
• Study Completion: August 18, 2022
• Last Updated: April 1, 2026

Record last verified: 2026-03

Locations

SY (1)